Sanofi Speeds Up Beyfortus Shipments Ahead of 2025-2026 RSV Season
The Pharma Data
JUNE 9, 2025
According to Thomas Triomphe, Executive Vice President of Vaccines at Sanofi, the product has been administered to over 250,000 infants in real-world settings, backed by more than 40 studies demonstrating its effectiveness in preventing RSV lower respiratory tract disease.
Let's personalize your content